Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAGM vs CAG as salvage therapy in relapsed/refractory AML-M4/M5
ChiCTR2000041011Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of cytarabine, aclarubicin, filgrastim and sargramostim in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall response rate (efficacy rate). Started Dec 2020; status: recruiting.
02
Drugs
cytarabineaclarubicinfilgrastimsargramostim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000041011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041011.